Roche has filed an investigational new drug application (IND) for a fourth Genmab antibody developed under the companies’ collaboration.

The companies are developing the antibody to block the interaction of the OX40 ligand and its receptor for the treatment of asthma. 

Under the agreement, Genmab develops capabilities to create human antibodies to a broad range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products.